Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB571 in Advanced Non-Small Cell Lung Cancer With MET Abnormalities
NCT07308106Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SKB571 in non-small cell lung cancer (NSCLC), sponsored by Kelun-Biotech. Started Apr 2026; status: recruiting.
02
Drugs
SKB571
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07308106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308106.